GeoVax Revenue and Competitors

Atlanta, GA USA

Location

$28M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • GeoVax's estimated annual revenue is currently $2.5M per year.(i)
  • GeoVax's estimated revenue per employee is $77,500
  • GeoVax's total funding is $28M.

Employee Data

  • GeoVax has 32 Employees.(i)
  • GeoVax grew their employee count by 33% last year.

GeoVax's People

NameTitleEmail/Phone
1
CFOReveal Email/Phone
2
VP, Head QualityReveal Email/Phone
3
VP Regulatory AffairsReveal Email/Phone
4
Head Commercial Development & OperationsReveal Email/Phone
5
Director, Project Management | BiotechReveal Email/Phone
6
Chief Medical OfficerReveal Email/Phone
7
DirectorReveal Email/Phone
8
Director HIV VaccinesReveal Email/Phone
9
Chief Scientific OfficerReveal Email/Phone
10
Director, Vaccine DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$1.7M11-8%N/AN/A
#3
$2.3M1550%N/AN/A
#4
$1.1M70%N/AN/A
#5
$17.1M1105%$0.07BN/A
#6
$4M26-7%N/AN/A
#7
$0.8M50%N/AN/A
#8
$1.1M717%N/AN/A
#9
$7.8M502%N/AN/A
#10
$1.7M1110%N/AN/A
Add Company

What Is GeoVax?

GeoVax is a Biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus - AIDS) and other infectious agents. Our goals include: developing AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting phase I/II and III human trials for vaccine safety and effectiveness and obtaining regulatory approval of these vaccines in the USA and specified international markets. Outstanding preclinical results: GeoVax DNA/MVA vaccine protected 96% of non-human primates for over 3½ yrs. To our knowledge, this level of protection has not been achieved by other candidate vaccines.

keywords:Biotechnology

$28M

Total Funding

32

Number of Employees

$2.5M

Revenue (est)

33%

Employee Growth %

N/A

Valuation

N/A

Accelerator

GeoVax News

2022-04-20 - USPTO Issues Malaria Vaccine Patent to GeoVax

GeoVax Labs, a biotechnology company focused on the development of vaccines and immunotherapies, announced on April 26, 2022 that the US...

2022-04-20 - USPTO Issues Malaria Vaccine Patent to GeoVax

GeoVax Labs, a biotechnology company focused on the development of vaccines and immunotherapies, announced on April 26, 2022 that the US...

2022-04-17 - GeoVax Announces Issuance of Malaria Vaccine Patent

GeoVax's Unique Multi-Antigenic Vaccine Approach Designed to Provide Stronger, Broader Protection Against Malaria Atlanta, GA, April 26,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.9M327%N/A
#2
$2.6M3310%N/A
#3
$7.1M333%N/A
#4
N/A333%N/A
#5
$7.9M34-3%N/A